MAIA Biotechnology (MAIA) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MAIA Biotechnology is the larger company by market cap ($68.5 million vs $66.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAIA | PLYX |
|---|---|---|
| Share price | $1.11 | $1.33 |
| Market cap | $68.54M | $66.30M |
| 1-day change | -2.63% | -11.92% |
| YTD return | -27.45% | — |
| 1-year return | +21.71% | — |
| EPS (TTM) | $-0.47 | $-0.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-22.40M | $-8.98M |
| 52-week high | $3.19 | $48.91 |
| 52-week low | $0.895 | $1.30 |
| Distance from 52-week high | -65.20% | -97.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +981.08% | +463.91% |
| Average volume | 524.29K | 36.42K |
| Shares outstanding | 61.75M | 49.85M |
| Employees | 13 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
MAIA vs PLYX FAQ
Which is bigger, MAIA Biotechnology or Polaryx Therapeutics?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $68.54M compared with $66.30M for Polaryx Therapeutics (PLYX).
Are MAIA Biotechnology and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.